IKT · NASDAQ · Biotechnology

Inhibikase Therapeutics (IKT)

Develops IKT-001 as a clinical-stage therapy for pulmonary arterial hypertension.

$2.31
After hours−0.01 (−0.43%)
At close$2.32(+5.45%)